Vaccitech Newsroom

Newsroom

News & updates

New UK-China biotech collaboration to develop shingles vaccine

Vaccitech will combine Oxford University vaccine know-how with the manufacturing expertise of China’s CanSino Biologics in collaboration focused on herpes zoster. Vaccitech Limited, a UK-based company developing products to treat and prevent multiple infectious...

Vaccitech are looking for a Manufacturing Project Manager

Position Summary Vaccitech is seeking a Project Manager for a hands-on role. The Project Manager will support the manufacturing of our vaccine and therapeutic products, and actively engage with contract manufacturing organisations, contract test labs, and Vaccitech...

Universal Flu Vaccine Data Presented at NFID 2018

Data on safety and immunogenicity of Vaccitech’s flu vaccine have been presented at the 2018 Annual Conference on Vaccinology Research, run by the National Foundation for Infectious Diseases. The presentation was entitled: A Clinical Study to Determine the Safety and...

Flu vaccine Study Recruits First Participants

The world’s first NHS trial for a universal flu vaccine has recruited its first round of participants, with over 862 people signing up to take part since the trial launched in October 2017. This marks the end of the first phase of the trial, which will open again for...

Vaccitech secures £20m Series A with GV, OSI and Sequoia China

Vaccitech, an Oxford University spinout company developing a universal flu vaccine, among other vaccine-related products, has secured £20m ($27.1m) in Series A financing. The round was co-led by new investors GV, Sequoia China, and existing backer Oxford Sciences...

World-First NHS Trial For Universal Flu Vaccine

The world’s first widespread human testing of a flu vaccine which researchers hope will protect more over 65-year-olds against influenza has begun in the NHS. More than 2,000 people aged 65 and over will be asked to take part in a study supported by the National...

Vaccitech Launch RIVET Study

Vaccitech has engaged with Primary Care Clinical Trial Unit at Oxford University to run a small pilot study entitled RIVET (Re-inventing Influenza vaccine Efficacy Trials) as a precursor to its large phase IIb (INVICTUS) novel influenza vaccine study scheduled to...